在HPTN069/ACTG5305第二阶段PrEP试验中的药理学药物检测和自我报告的坚持
Stanley E Cooper1, Shuaiqi Zhang2, Daniel Haines2
1Division of Infectious Diseases, Weill Cornell Medicine, 525 East 68th Street, Baker 24, New York, NY, 10065, USA. sec9059@med.cornell.edu.
AIDS and behavior
|July 31, 2024
概括
坚持暴露前预防 (PrEP) 对于疗效至关重要. 这项研究发现,虽然许多参与者报告了每天的坚持,但实际的药物度往往表明了相反的情况,强调了在PrEP试验中需要更好的坚持支持的需要.
科学领域:
- 临床药理学 临床药理学
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 坚持暴露前预防 (PrEP) 对于其在预防艾滋病毒方面的有效性至关重要.
- 临床试验需要准确的遵守评估来解释疗效数据.
研究的目的:
- 在PrEP试验中,将自我报告的坚持与测量的血药物度进行比较.
- 识别与自我报告和测量的坚持之间的差异相关的因素.
主要方法:
- 在HPTN069/ACTG5305试验中,评估了候选PrEP疗程的安全性和耐受性.
- 血药物度和计算机辅助自访 (CASI) 坚持数据是在24周和48周收集的.
- 一个通用的线性模型分析了人口统计,自我报告的坚持和药物度之间的关联.
主要成果:
- 65%的观察结果的药物度与每日坚持一致,而只有43%的人通过CASI.com报告了每日坚持.
- 11%的人报告每天坚持使用,但药物度低于每日使用.
- 诸如出生时被分配为男性,年龄较大,白人种族,高等教育,就业和伴侣/结婚等因素与更高的坚持有关.
- 没有工作或单身/没有伴侣与较低的坚持有关.
结论:
- 在PrEP试验中,自我报告和测量的坚持之间存在差异是常见的.
- 人口统计和社会经济因素影响了坚持.
- 持续的坚持咨询对于PrEP临床试验的成功至关重要.
相关概念视频
Pharmacovigilance
805
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
805
Drug Concentrations: Measurements
352
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
352
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K


